Tue Jun 03 12:20:00 UTC 2025: **Hims & Hers Stock Soars on GLP-1 Demand, But Future Growth Faces Scrutiny**
**San Francisco, CA** – Hims & Hers Health (HIMS), a telehealth company connecting consumers with healthcare services and products, has experienced a rollercoaster year on the stock market in 2025, ultimately surging over 120% year-to-date. The company’s success is largely attributed to its ability to capitalize on the booming demand for GLP-1 drugs, such as Ozempic and Mounjaro, through its online platform, offering more affordable and accessible options to consumers.
Revenue has skyrocketed, reaching $1.8 billion in 2025, a significant increase from $100 million in 2019, representing a 79% compound annual growth rate (CAGR) over five years. The company’s first-quarter 2025 earnings report showed triple-digit growth in both revenue (up 111% to $586 million) and net income (up 345% to $49.5 million).
While GLP-1 drugs have fueled much of the company’s growth, Hims & Hers has also seen success in other areas, including mental health, sexual wellness, and hair loss treatments. The company’s ability to adapt and scale quickly has been a major advantage, especially during drug shortages.
Despite the impressive growth, concerns are growing about the company’s valuation. While Hims & Hers projects strong growth through 2030, some analysts believe the stock may be overvalued at its current price. The company’s long-term guidance projects revenues of $6.5 billion and adjusted EBITDA of $1.3 billion by 2030.
Wall Street analysts are currently more cautious than optimistic on HIMS, with an average price target of $45.50, suggesting a potential downside of almost 15% over the next twelve months.
Given the stock’s volatility and a short interest of 34.5% of the float, investors are advised to proceed with caution and consider waiting for a potential pullback before investing.
First Piper 